[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tension-headache\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tension-headache":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100625054","effect-of-laser-acupuncture-on-tension-headache-in-post-pubertal-females-100625054",false,"NCT07417644","Effect of Laser Acupuncture on Tension Headache in Post-Pubertal Females","Inclusion Criteria:\n\n* Their age will be ranged from 15 to 18 years.\n* Their body mass index (BMI) will be ranged from 20-25 Kg\u002Fm2.\n* All participants will be diagnosed with tension type headache for which they haven't receive any treatment in the previous two weeks.\n* Pain quality is typically pressing or tightening of mild to moderate intensity, bilateral in location and not worsening during routine physical activity.\n* Absence of nausea and vomiting.\n\nExclusion Criteria:\n\n* Patients with other causes of headache.\n* Patients who have pulsating headaches, neurological deficits or metabolic disorders.\n* Contraindications to treatment (other simultaneous treatment, localized skin infection, fear).\n* Previous head trauma.\n* Previous physical therapy treatment for tension type headache during the last 6 months.","FEMALE","15 Years","18 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study will be carried out to evaluate the effect of laser acupuncture on tension headache in post-pubertal females.",[26],"Tension Headache","NOT_YET_RECRUITING","2026-02-11",{"date":30,"type":31},"2026-02-18","ACTUAL",{"date":33,"type":20},"2026-02-20",{"date":35,"type":20},"2026-05-30",{"name":37,"class":38},"Cairo University","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":53,"conditions":54,"keywords":59,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":39},"100537379","nvns-for-the-prevention-and-treatment-of-primary-headache-100537379","NCT06277063","nVNS for the Prevention and Treatment of Primary Headache","Noninvasive Vagus Nerve Stimulation for the Prevention and Treatment of Primary Headache: a Single-arm Single-center Clinical Trial.","Inclusion Criteria:\n\n1. Patients with migraine, cluster headache and tension-type headache were diagnosed according to Chinese Guidelines for the diagnosis and Treatment of Migraine (2022 edition) and Chinese Guidelines for the diagnosis and treatment of cluster headache (2022 edition).\n2. Age \\>=7 years old, \\\u003C=20 years old;\n3. Patients have experienced headache on 3-15 days per month in the past;\n4. Maintain a stable dose and frequency of medication and do not take new drugs during the course of participating in the trial;\n5. They volunteered to participate in the trial and signed informed consent.\n\nExclusion Criteria:\n\n1. History of secondary headache, aneurysm, intracranial hemorrhage, brain tumor, severe head trauma, drug abuse, addiction, syncope, or seizures;\n2. prior migraine-preventive surgery, cervical vagotomy, or implantation of an electronic or neurostimulator device;\n3. Simultaneous use of other devices (e.g., TENS devices, muscle stimulators);\n4. An implantable medical device in use, such as a pacemaker, hearing aid, or any implantable electronic device;\n5. underwent head and neck nerve block within the past 2 months;\n6. Opioid use (more than 2 days per month); Use of analgesics alone or non-steroidal anti-inflammatory drugs (more than 15 days per month); Or tamoxifen, ergots or combination analgesics (more than 10 days per month);\n7. Patients who underwent cervical vagotomy (cervical vagotomy);\n8. Pediatric patients (under 6 years old); Pregnant women;\n9. Patients with clinically significant hypertension, hypotension, bradycardia or tachycardia;\n10. Patients with congenital heart disease;\n11. Mental\u002Fcognitive disorders, etc.","ALL","7 Years","20 Years",{"count":51,"type":20},15,[23],"This study is a single-center, single-arm study. All subjects will receive the same treatment.\n\nChildren and adolescents (7-20 years old) with migraine who met the inclusion criteria will be enrolled as subjects in the experimental group, and the changes in headache scores before and after the intervention will be compared. The intervention method is as follows: ictal intervention, in which subjects will be evaluated for headache improvement after a short intervention during an acute exacerbation. By wearing a vagus stimulator, the stimulating electrode will be located in the concha region rich in vagus nerve fiber endings, and the appropriate stimulation intensity will be adjusted for stimulation.\n\nTherefore, this study will verify the effect of nVNS on the acute treatment of primary headache in children and adolescents. Based on the electrocardiogram and electromyography indicators during the intervention process of nVNS, an objective evaluation system for the improvement of headache by nVNS is established, and the role of stimulation parameters on the effect is further explored to realize the optimization of parameters.",[55,56,57,58,26],"Primary Headache","Migraine in Adolescence","Migraine in Children","Cluster Headache",[60,61,62],"Primary headache","Adolescents","Noninvasive vagus nerve stimulation","RECRUITING","2025-08-06",{"date":66,"type":31},"2025-08-12",{"date":68,"type":31},"2024-12-05",{"date":70,"type":20},"2026-12-30",{"name":72,"class":38},"Nanfang Hospital, Southern Medical University",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":47,"minAge":17,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":21,"phases":82,"briefSummary":84,"conditions":85,"keywords":89,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":39},"100588130","phase-3-05-bupivacaine-lower-cervical-intramuscular-injection-vs-iv-medications-for-headache-treatment-100588130","NCT06937385","0.5% Bupivacaine Lower Cervical Intramuscular Injection vs IV Medications for Headache Treatment","Randomized, Prospective, Open-label, Controlled Trial of 0.5% Bupivacaine Lower Cervical Intramuscular Injection vs IV Medications in Treatment of Non-Traumatic Headache in the Emergency Department","Inclusion Criteria:\n\n* Patient has to be able to provide own consent\n* English-speaking only\n* Non traumatic headache with VAS pain score of 5 or above out of 10\n\nExclusion Criteria:\n\n* traumatic headache\n* Confused patients\n* allergy to bupivacaine\n* infection over injection site\n* recent neck surgery\n* hemodynamically unstable\n* bleeding disorder\n* anticoagulation use\n* pregnant, lactating women\n* prisoners",{"count":81,"type":20},100,[83],"PHASE3","Headache is a frequent chief complaint among patients presenting to the Emergency Department (ED), accounting for 2.1 million visits annually in the United States. Often, individuals resort to ED care only after over-the-counter or home remedies have failed, leading to the predominant use of intravenous (IV) medications in the ED, including NSAIDs, triptans, neuroleptics, antiepileptics, and dopaminergic antagonists. Unfortunately, these pharmacologic treatments frequently induce side effects such as cognitive impairment, extrapyramidal reactions, and the potential for medication dependency. In the ED, patients frequently require concurrent administration of multiple systemic medications to achieve satisfactory pain relief, thereby elevating the risk associated with medication use. Despite these medication regimens, a significant portion of patients continue to experience inadequate pain relief. Consequently, the search for an optimal headache therapy-characterized by rapid and effective pain relief, long lasting results, minimal side effects, and allows for rapid ED patient turnover-continues to be a popular area of research in emergency medicine. The investigators plan to evaluate the use of 0.5% bupivacaine cervical IM injection at the c6-7 location for the treatment of non traumatic headaches using a non-inferiority design, randomized, prospective, open-label, controlled trial comparing it to physicians choice of intravenous medications in treatment of headache in the Emergency Department at North Florida Hospital.",[86,87,26,88],"Headache","Migraine","Occipital Neuralgia",[90,91,92,93],"headache","bupivicaine","cervical injection","paraspinous injection","2025-04-21",{"date":96,"type":31},"2025-04-24",{"date":98,"type":20},"2025-05-01",{"date":100,"type":20},"2026-05-01",{"name":102,"class":38},"HCA Florida North Florida Hospital"]